ArticleOncology letters2025
Lymphedema is a rare manifestation of lymphoma: A case series and literature review.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphedema, which is characterized by impaired lymphatic drainage leading to tissue swelling, represents a relatively uncommon clinical entity, with an estimated prevalence of <1% being observed in the general population. Although most cases arise from postsurgical complications or filariasis, lymphoma-associated lymphedema remains an exceedingly rare manifestation, with only 19 cases documented in the medical literature prior to the present study. The current study presented a case series of 11 patients with histologically confirmed lymphoma manifesting with lymphedema, which represents the largest single-center report to date. In the present cohort spanning a time period from 2007-2024, patients who initially presented with refractory lymphedema (9 lower extremity cases, 1 upper extremity case and 1 systemic case) subsequently received a diagnosis of lymphoma via comprehensive evaluation, including imaging (100% detection rate on CT/MRI) and histopathology examinations. The median latency from edema onset to lymphoma diagnosis was 7 months (range, 1-24 months), with 72.7% (8 out of 11) of the patients demonstrating B-cell lineage predominance. The present case series underscored the notion that although lymphedema secondary to lymphoma constitutes <0.5% of all secondary lymphedema cases, it warrants consideration in patients with atypical presentations, such as rapid progression (54.5%), systemic symptoms (81.8%) or abnormal tumor markers (66.7%). The present case report findings emphasized the idea that lymphoma should be included in the differential diagnosis of unexplained lymphedema, particularly when accompanied by warning signs such as lymphadenopathy (100% imaging positivity) or hematologic abnormalities (45.5% anemia prevalence).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.